Disease · MONDO_0021640

grade III glioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. grade III glioma. Diseases, record MONDO_0021640. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021640

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: grade III glioma; Open Targets
Open Targets ID: MONDO_0021640; Open Targets
Other names: WHO grade III glioma, anaplastic glioma; Open Targets
NCI Thesaurus: C127816; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 36 drugs, from ClinicalTrials.gov; Open Targets

Drugs36

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
LOMUSTINE	CHEMBL514	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PROCARBAZINE	CHEMBL1321	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
6-O-BENZYLGUANINE	CHEMBL407874	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CARMUSTINE	CHEMBL513	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 36

See all 36 drugs

Targets93

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	3	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	3	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 1/2	https://conductscience.org/library/genes/2280	Drugs and targets

1 to 10 of 93

See all 93 targets

Trials35

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00626990	Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)	Phase 3	751	2023-09-11	Brain and Central Nervous System Tumors	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00392171	The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)	Phase 2	120	2010-05-17	Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00995007	A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas	Phase 2	112	2016-03-29	Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma	CARBOPLATIN, VANDETANIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00923117	Sunitinib to Treat Recurrent Brain Cancer	Phase 2	87	2013-06-25	Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT01434602	Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	Phase 1/2	86	2022-02-01	Brain Tumor, Glioblastoma, Anaplastic Glioma	EVEROLIMUS, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00412542	Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas	Phase 2	78	2012-02-28	Glioblastoma Multiforme, Glioma	IRINOTECAN, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00504660	6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients	Phase 2	75	2012-01-11	Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer	CAPECITABINE, CELECOXIB, LOMUSTINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00112736	Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma	Phase 1/2	69	2015-06-15	Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor	ERLOTINIB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00369590	VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide	Phase 2	58	2015-10-02	Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00671970	Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)	Phase 2	57	2013-05-13	Glioblastoma, Gliosarcoma	BEVACIZUMAB, ERLOTINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 35

See all 35 trials

Comparisons in its trials16

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: Number of Participants With Adverse Events	44 of 44	43 of 43	87	NCT00923117	Trial comparisons
Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: serious adverse events	16 of 44	13 of 43	87	NCT00923117	Trial comparisons
Phase I (Erlotinib & Temsirolimus) vs Phase II (Erlotinib & Erlotinib): serious adverse events	3 of 21	2 of 59	80	NCT00112736	Trial comparisons
Anaplastic Tumors vs Glioblastoma Multiforme: serious adverse events	8 of 31	16 of 43	74	NCT00504660	Trial comparisons
Arm I - Anaplastic Glioma vs Arm 2 - Glioblastoma: Safety Profile - Events That Discontinued Treatment	8 of 16	6 of 42	58	NCT00369590	Trial comparisons
Phase 1 Dose Escalation - Romidepsin vs Phase 2 Dose From Phase 1 - Romidepsin: serious adverse events	0 of 8	0 of 40	48	NCT00085540	Trial comparisons
Treatment (Bendamustine Hydrochloride) for Glioblastoma vs Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma: Toxic Death	0 of 16	0 of 29	45	NCT00823797	Trial comparisons
Treatment (Bendamustine Hydrochloride) for Glioblastoma vs Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma: PFS-6	1 of 16	8 of 29	45	NCT00823797	Trial comparisons
Tandutinib & Bevacizumab in GBM Patients vs Tandutinib & Bevacizumab in AG Patients: Number of Participants With Adverse Events	40 of 41	1 of 1	42	NCT00667394	Trial comparisons
Tandutinib & Bevacizumab in GBM Patients vs Tandutinib & Bevacizumab in AG Patients: serious adverse events	15 of 41	0 of 1	42	NCT00667394	Trial comparisons

1 to 10 of 16

See all 16 comparisons in its trials

Papers from its trials26

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33783067	RESULT	1	PubMed
24470557	RESULT	1	PubMed
20308655	RESULT	1	PubMed
19289491	RESULT	1	PubMed
18850068	RESULT	1	PubMed
16533878	RESULT	1	PubMed
16192602	RESULT	1	PubMed
15514370	RESULT	1	PubMed
14769140	RESULT	1	PubMed
41449147	DERIVED	1	PubMed

1 to 10 of 26

See all 26 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021640

GET https://conductscience.org/api/diseases/v1/MONDO_0021640/drugs?page=2

API reference For AI assistants